Literature DB >> 1053567

Anorectal and perianal complications of hematologic malignant neoplasms.

M B Musa, S B Katakkar, A Khaliq.   

Abstract

Among 17 adults with hematologic malignant neoplasms in whom anorectal complications developed, the overall mortality was 53%; for those in whom the disease was not in remission the mortality was 69%, compared with zero for patients who were in remission. All but one of the deaths were directly attributable to septicemia secondary to the anorectal lesion. Over half of the patients had a history of previous anorectal problems or disordered bowel pattern preceding the anorectal complication. The anorectal lesions affecting these 17 patients included prolapsed hemorrhoids (in 5); discrete ulcers in the anal canal and surrounding cellulitis (8); necrosis of the anus and perianal area (2); and perirectal abscesses (2). Only the abscesses responded to surgical drainage. Treatment of the other lesions was conservative: bowel function was maintained as normal as possible, good perineal hygiene was practised and stool softeners were used, while efforts were directed towards achieving remission of the hematologic neoplastic disease.

Entities:  

Mesh:

Year:  1975        PMID: 1053567

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  3 in total

1.  Histopathological changes in haemorrhoid associated mucosa and submucosa.

Authors:  S M Kaftan; N Y Haboubi
Journal:  Int J Colorectal Dis       Date:  1995       Impact factor: 2.571

Review 2.  Management of acute perianal sepsis in neutropenic patients with hematological malignancy.

Authors:  B Baker; M Al-Salman; F Daoud
Journal:  Tech Coloproctol       Date:  2013-11-26       Impact factor: 3.781

3.  Anorectal Complications During Neutropenic Period in Patients with Hematologic Diseases.

Authors:  Soner Solmaz; Aslı Korur; Çiğdem Gereklioğlu; Süheyl Asma; Nurhilal Büyükkurt; Mutlu Kasar; Mahmut Yeral; İlknur Kozanoğlu; Can Boğa; Hakan Ozdoğu
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-03-01       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.